• Binokrit (prefilled syringes) Epoetin Alfa

Buy Binokrit in prefilled syringes, 6 syringes in box.

Active substance: Epoetin Alfa(rDNA origin)

Structural analogs: EPOGEN, EPREX, Procrit, Binocrit, ERYPO, EPOCRIN, Abseamed

Binokrit: 6 x 2000iu 


Pharmacodynamics - 


Erythropoietin is a glycoprotein that stimulates erythropoiesis, activates mitosis and maturation of erythrocytes from progenitor cells of the erythrocyte series.
The molecular weight of erythropoietin is about 32,000-40,000 daltons. The protein fraction is about 58% of the molecular weight and includes 165 amino acids.
Four hydrocarbon chains are linked to the protein by three N-glycosidic bonds and one O-glycosidic linkage. Epoetin alfa obtained using genetic engineering technology is a purified glycoprotein,
it is identical in amino acid and carbohydrate composition to human erythropoietin isolated from urine in patients with anemia.
Binocrit ®has the highest possible degree of purification in accordance with modern technological capabilities.
In particular, when quantitatively analyzing the active substance of Binocrit ®The biological activity of epoetin alfa has been confirmed in an in vivo experiment (studies were carried out on healthy rats and rats with anemia, as well as in mice with polycythemia). After the administration of epoetin alfa, the number of erythrocytes, reticulocytes, hemoglobin concentration and ⁵⁹Fe absorption rate increase.
In vitro studies with incubation with epoetin alfa, an increase in the incorporation of ³H-thymidine in erythroid nucleus-containing spleen cells (in mouse spleen cell culture) was found.
Studies on the culture of human bone marrow cells have shown that epoetin alfa specifically stimulates erythropoiesis and has no effect on leukopoiesis.
Cytotoxic effects of epoetin alfa on human bone marrow cells have not been revealed. Erythropoietin is a growth factor that mainly stimulates the formation of red blood cells.
Receptors to erythropoietin may be present on the surface of various tumor cells. Administration of epoetin alfa is accompanied by an increase in the level of hemoglobin, hematocrit, serum iron, which improves blood supply to tissues and the work of the heart. The most significant effect of epoetin alfa was observed in anemia caused by chronic renal insufficiency, and also developed in patients with a number of malignant neoplasms and systemic diseases. that promotes improvement of blood supply of tissues and work of the heart.
The most significant effect of epoetin alfa was observed in anemia caused by chronic renal insufficiency, and also developed in patients with a number of malignant neoplasms and systemic diseases. that promotes
improvement of blood supply of tissues and work of the heart.
The most significant effect of epoetin alfa was observed in anemia caused by chronic renal insufficiency, and also developed in patients with a number of malignant neoplasms and systemic diseases.

 

 Pharmacokinetics

  Intravenous administration

 The half-life (T 1/2 ) of epoetin alfa after repeated intravenous administration is about 4 hours in healthy volunteers and about 5 hours in patients with chronic renal failure. In children, T 1/2 epoetin alfa is about 6 hours.


  Subcutaneous administration

 With subcutaneous administration, the concentration of epoetin alfa in the blood plasma is determined to be significantly lower than with intravenous administration, the time to reach the maximum concentration (C max ) of epoetin alfa in blood plasma is about 12- 18 h after administration. C max epoetin alfa with subcutaneous administration is only 1/2 part of the concentration with intravenous administration.

 The drug does not have the ability to cumulate - the concentration of epoetin alfa in the blood plasma after 24 hours after the first injection is determined the same as after 24 hours after the last injection. When subcutaneous injection of T 1/2 epoetin alfa is difficult to determine, it is about 24 hours. Bioavailability of epoetin alfa with subcutaneous injection is significantly lower than when administered intravenously, and is about 20%. 



Indications for use

Anemia in adults and children due to chronic renal failure (CRF), including


Contraindications

anemia due to chronic renal failure (CRF) in children and adults on hemodialysis, as well as in adults on peritoneal dialysis;
severe anemia of renal genesis, accompanied by clinical symptoms in adults with CRF who have not yet undergone hemodialysis;

treatment of anemia and reduced need for blood transfusion in adults receiving chemotherapy for solid tumors, malignant lymphoma or multiple myeloma, as well as for people at high risk of complications of blood transfusion due to the general severe condition (due to cardiovascular diseases, if anemia was noted before chemotherapy was initiated);

to increase the efficiency of autologous blood transfusion within the limits of a pre-surgical blood collection program before surgery in patients with a hematocrit level of 33-39% to facilitate the collection of autologous blood and reduce the risk associated with the use of allogeneic blood transfusions if the expected need for transfused blood exceeds the amount , which can be obtained by autologous collection without the use of epoetin alfa. Treatment is indicated for patients with moderate anemia (hemoglobin concentration 10-13 g / dL or 6.2-8.1 mmol / L), without iron deficiency, if significant blood loss is suspected, as well as in extensive surgical interventions, when large volume of transfused blood (5 or more volumes in men, 4 or more in women);


to reduce the risk for allogeneic blood transfusion in adults who do not have iron deficiency, before an elective orthopedic operation, in the presence of a high risk of complications during blood transfusion.
The use of the drug is limited - only in patients with moderate anemia (for example, at a hemoglobin concentration of 10-13 g / dL), if they are not included in the autologous blood collection program before the operation with the expected blood loss of 900 to 1800 ml;


anemia in HIV-infected patients receiving zidovudine therapy, with an endogenous erythropoietin level of less than 500 IU / ml.


hypersensitivity to the active substance or to any component included in the preparation.

partial red cell aplasia (PKAA), which appeared after treatment with erythropoietin;

uncontrolled arterial hypertension;

surgical patients who for whatever reason can not receive effective treatment for the prevention of thrombosis;

myocardial infarction or stroke that occurred within 1 month before the planned treatment; unstable angina; patients with a high risk of deep vein thrombosis and thromboembolic disease in the anamnesis (as part of increasing the efficiency of autologous blood transfusion);

severe damage to the coronary, peripheral, carotid arteries, as well as cerebral vessels, including in patients who recently underwent myocardial infarction or stroke (within the limits of the pre-op program for collecting blood before an extensive surgical operation and not participating in the autologous blood transfusion program);

all contraindications associated with the autoblood backup program relate to patients who are on epoetin alfa treatment.


Contraindications

hypersensitivity to the active substance or to any component included in the preparation.

partial red cell aplasia (PKAA), which appeared after treatment with erythropoietin;

uncontrolled arterial hypertension;
surgical patients who for whatever reason can not receive effective treatment for the prevention of thrombosis;

myocardial infarction or stroke that occurred within 1 month before the planned treatment;

unstable angina; patients with a high risk of deep vein thrombosis and thromboembolic disease in the anamnesis (as part of increasing the efficiency of autologous blood transfusion);

severe damage to the coronary, peripheral, carotid arteries, as well as cerebral vessels, including in patients who recently underwent myocardial infarction or stroke (within the limits of the pre-op program for collecting blood before an extensive surgical operation and not participating in the autologous blood transfusion program);

all contraindications associated with the autoblood backup program relate to patients who are on epoetin alfa treatment.

Write a review

Note: HTML is not translated!
    Bad           Good

Binokrit (prefilled syringes) Epoetin Alfa

  • Product Code: EPO
  • Availability: In Stock
  • 220.00€


Related Products

Eralfon (prefilled syringes) Epoetin Alfa

Buy Eralfon in prefilled syringes, 6 syringes in box.Active substance: Epoetin Alfa(rDNA origin)Stru..

200.00€

Recormon 2000IU x 6

Recormon (Epoetin) is used to treat severe anemia. Release form, composition and packing: Colo..

240.00€

Mircera 100MCG 0.3ml |Russian Pharmacy Product

Buy Mircera(CERA) 100mcg/0.3ml RocheBuy Mircera injection online. - methoxy polyethylene glycol..

240.00€

Mircera 75 MCG 0.3ml |Russian Pharmacy Product

Buy Mircera(CERA) 75mcg/0.3ml Roche Buy Mircera injection o..

190.00€

Mircera 75 - 200 MCG |EU

Buy Mircera(CERA) 100mcg/0.3ml RocheBuy Mircera injection online. - methoxy polyethylene glycol..

245.00€

Tags: binokrit, epoetin alfa